Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baidi Quzhi (BDQZ) is a Traditional Chinese Medicine (TCM) granule formulation developed by Shanghai Yueyang Integrated Medicine Hospital for the treatment of acne vulgaris. It is an oral medication typically administered twice daily. In clinical research, it is being evaluated for its efficacy, safety, and recurrence control in patients with mild to moderate acne, often in a combination therapy regimen with topical Ju Yin (JY) cream. As a TCM product, it likely contains a complex mixture of herbal extracts designed to address the multi-factorial nature of acne, although its specific chemical constituents and molecular targets are not publicly detailed in current clinical trial documentation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baidi Quzhi granule.